Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis

• Market Cap: ₹1.26B
• Dividend Yield: N/A
• Average Volume (3M): 726.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: -46.31%
• EPS Growth: -26.28%
• Country: IN
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.45
• Shares Outstanding: 21,560,587
• 10 Day Avg. Volume: 346
• 30 Day Avg. Volume: 726
• PEG Ratio: -0.15
• Price to Book (P/B): -1.00
• Price to Sales (P/S): 3.37
• P/FCF Ratio: -12.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ₹60.00 ▼(-15.49% Downside)
• Action: Reiterated Date: 04/08/26
• Date: Action: Reiterated 04/08/26

The score is held down primarily by very weak financial performance (ongoing losses, negative equity/leverage risk, and negative operating/free cash flow). Technical indicators are mixed with only modest near-term strength and still-negative MACD. Valuation is also constrained by negative earnings and no stated dividend support.

Positive Factors

B2B manufacturing model

Krebs' core revenue comes from selling manufactured biochemical and chemical products to industrial buyers. B2B supply relationships are often contract-driven and recurrent, providing customer stickiness and revenue visibility that support operational stability over a multi-month horizon.

Negative Factors

Persistent unprofitable operations

Krebs has sustained negative net income and EBIT margins across reporting periods, signaling operational losses that erode reinvestment capacity. Continued unprofitability weakens competitive positioning, reduces ability to fund improvements, and increases reliance on external financing over the medium term.

Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model

Company Description

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione,...

Read more

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione,...

How the Company Makes Money

The company primarily makes money through the sale of its manufactured biochemical/chemical products to customers (typically industrial buyers) under B2B supply arrangements. Revenue is generated from product sales volumes multiplied by realized s...

Read more

The company primarily makes money through the sale of its manufactured biochemical/chemical products to customers (typically industrial buyers) under B2B supply arrangements. Revenue is generated from product sales volumes multiplied by realized s...

Krebs Biochemicals & Industries Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	272.16M	433.12M	504.21M	521.34M	597.03M	386.06M
Gross Profit	207.34M	377.56M	-108.75M	244.19M	-57.64M	-136.26M
EBITDA	-143.95M	-143.21M	-82.73M	-151.62M	-328.46M	-169.63M
Net Income	-274.74M	-269.39M	-197.28M	-246.92M	-445.27M	-283.59M
Balance Sheet
Total Assets	1.68B	1.69B	1.78B	1.75B	1.90B	1.59B
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.38M	1.37M	858.00K	1.01M	7.11M
Total Debt	2.19B	2.12B	2.39B	1.83B	1.88B	1.11B
Total Liabilities	3.26B	3.15B	2.97B	2.74B	2.65B	2.02B
Stockholders Equity	-1.58B	-1.46B	-1.19B	-994.62M	-750.93M	-427.33M
Cash Flow
Free Cash Flow	-37.27M	-114.54M	-70.50M	-355.84M	-407.36M	-400.81M
Operating Cash Flow	-16.76M	-78.91M	23.65M	-247.13M	-172.16M	-145.75M
Investing Cash Flow	-21.83M	-49.70M	-78.17M	-126.45M	-229.00M	-225.49M
Financing Cash Flow	38.44M	128.65M	55.64M	373.43M	395.06M	376.61M

Krebs Biochemicals & Industries Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 71.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Positive. The current price of 71 is above the 20-day moving average (MA) of 50.51, above the 50-day MA of 54.74, and above the 200-day MA of 68.82, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 58.95 is Neutral, neither overbought nor oversold. The STOCH value of 76.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KREBSBIO.

Krebs Biochemicals & Industries Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	64 Neutral	₹1.45B	21.48	―	―	14.53%	-10.49%
BAFNAPH	58 Neutral	₹3.14B	48.53	―	―	-0.77%	2055.99%
BALPHARMA	58 Neutral	₹1.20B	16.40	―	1.62%	-9.07%	5.36%
VAISHALI	52 Neutral	₹662.45M	21.33	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	47 Neutral	₹1.86B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	45 Neutral	₹1.26B	-11.90	―	―	-46.31%	-26.28%

Krebs Biochemicals & Industries Ltd. Corporate Events